



Knowledge and Awareness of Orbital Mucormycosis in Post COVID-19 Recovered Patients in India

Vishwdeep Mishra¹, Dr. Ragni Kumari^{2*}, Dr. Gaurav Kumar Bhardwaj³, MD Masihhuzzaman⁴, Dr. Kamal Pant⁵, Dr. Aditya Tripathi⁶, Sandhya Shakya⁷, Akshya Kumar⁸

¹Assistant Professor, Department of Optometry Era University, Lucknow, India

²Research Associate, Era University, Lucknow, India

³Associate Professor, Department of Optometry and Vision Science, Amity University, Haryana, India

⁴Assistant Professor, Department of Optometry and Vision Science, Amity University, Haryana, India

⁵Associate Professor, UP University of Medical Sciences, Saifai, Etawah, India

⁶Demonstrator, UP University of Medical Sciences, Saifai, Etawah, India

⁷Optometrist, Chaudharay Eye 7 Hospital, Lajpat Nagar, Delhi, India

⁸Assistant Professor, IIHT Paramedical & Nursing College, Deoband, U.P., India



WebLog Open Access Publications

Article ID - wjphe.2024.h2301
Author - Dr. Ragni Kumari, Ph.D.

OPEN ACCESS

*Correspondence:

Dr. Ragni Kumari, Research Associate,
Era University, Lucknow, India,
E-mail: ragnimishraa@gmail.com

Received Date: 31 Jul 2024

Accepted Date: 20 Aug 2024

Published Date: 23 Aug 2024

Citation:

Vishwdeep Mishra, Ragni Kumari,
Gaurav Kumar Bhardwaj, MD
Masihhuzzaman, Kamal Pant, Aditya
Tripathi. Knowledge and Awareness
of Orbital Mucormycosis in Post
COVID-19 Recovered Patients in India.
WebLog J Public Health Epidemiol.
wjphe.2024.h2301.

Copyright© 2024 Ragni Kumari. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The emergence of mucormycosis cases amid the COVID-19 pandemic and the fear associated with mucormycosis may turn out to be a terrifying public health issue. The current study aims to assess knowledge and awareness about orbital mucormycosis in post COVID-19 recovered patients.

Methods: A cross-sectional study was carried out among 242 COVID-19 recovered population from August 2021 to February 2022. A semi-structured online questionnaire was used for data collection using convenient and snow ball sampling methods.

Results: A total of 242 participants completed the questionnaire. Approximately 53.7% of participants were male and 46.3% were female. Most of the participants were working and were aware about mucormycosis through social media. Presenting symptoms and signs of COVID-19 were fever (87.6%), malaise (5.8%), weakness (72.3%), vertigo (5%), cough/cold (76.4%), shivering (22.3%), chills (23.1%), loss of taste (61.2%), rashes (25.6%) and rest were asymptomatic (5.8%) or presented with multiple signs and symptoms. A statistically significant association was found between reported history of mucor-mycosis and duration of steroid use (p value=0.003), being educated and aware about the disease (p value=0.000) and older age (p value=0.000).

Conclusion: Fungal infection and mucormycosis are not new phenomena but the emergence of mucormycosis associated with COVID-19 is a big concern. The current study highlighted the good awareness about mucor-mycosis among COVID-19 recovered patients in Indian population.

Keywords: Corticosteroid, COVID-19, Diabetes, Fungal co-infection, Mucormycosis, Rhino-orbito-cerebral mucormycosis, Steroid therapy

Introduction

Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome virus 2 (SARS-CoV-2), has affected more than 543 million people worldwide, accounting for over 6.3 million deaths as on 30th June 2022 [1]. The pandemic due to novel SARS Coronavirus-2 (COVID-19) continues to be a significant problem worldwide [2]. COVID-19-associated rhino-orbital-cerebral mucormycosis (ROCM) has reached epidemic proportion during India's second wave of COVID-19 pandemic, with several risk factors being implicated in its pathogenesis [3]. COVID-19 infection, its treatment, resultant immunosuppression, and pre-existing comorbidities have made patients vulnerable to secondary infections including mucormycosis [4].

The disease caused by the fungus has been reported all over the world and although associated with immunocompromised states like carcinomas or immunosuppressive therapy, it also affects a newer range of susceptible hosts like diabetics, neutropenics, patients on desferroxamine therapy, etc. [5]. The pandemic coronavirus disease 2019 (COVID-19) continues to be a significant problem

worldwide. While several treatment options have been evaluated, none except systemic glucocorticoids have been shown to improve survival in COVID-19 [6].

COVID-19 is a new disease condition caused by a novel coronavirus (SARS-CoV-2) first documented in Wuhan, China [7]. Mucormycosis is commonly associated with covid 19 disease in medically compromised individuals. Mucormycosis is an angio-invasive disease that is characterized by tissue infarction and necrosis. The mucormycosis are classified based on its anatomic location, such as rhino-orbital-cerebral (ROCM), pulmonary, gastrointestinal, cutaneous, renal and disseminated mucormycosis. ROCM mucormycosis is the commonest form (45-74%), followed by cutaneous (10-31%), pulmonary (3-22%), renal (0.5-9%), and gastrointestinal (2-8%) [8]. Higher risk of Mucormycosis is found in patients with diabetes mellitus, under chemotherapy, haematological malignancy, human immunodeficiency virus (HIV) infection, organ transplant recipients on immunosuppressive therapy. Globally, *Rhizopus arrhizus* is the commonest cause of mucormycosis [9]. The mortality rate of Mucormycosis in India is ranges from 28-52%, but there are limited studies in India on mucormycosis [8].

Previous studies have documented the epidemiology, clinical profile, management, and outcome of COVID-19-associated RCOM after Covid-19 recovery [10,11]. Numerous studies have documented presenting symptoms and sign and outcome of management of post COVID-19 patients in India [11-15]. However, there exist a gap about the knowledge and awareness of orbital mucor-mycosis in literature specially among Indian population. The current study aimed at assessing knowledge about mucor-mycosis and associated risk factors of the disease among patients who had recovered from COVID-19 in Northern India.

Methodology

A cross-sectional online study was conducted to assess knowledge and awareness about orbital mucor-mycosis in post COVID-19 patients. The participants were interviewed, using an online questionnaire that was developed specifically for this study. The inclusion criteria were all persons who had recovered from COVID-19 and gave informed consent for participation in the study. The study population comprised of all the COVID-19 recovered adults in India. The sample size of 242 was calculated using 4.3% prevalence of mucor-mycosis from previous studies, absolute precision of 2.5%, confidence level of 95% and a population size of 5000 [12]. The sampling technique was non-probability sampling comprising of convenience and snowball sampling methods. For data collection, a semi-structured online questionnaire (in "Google Form") was created and shared widely in social media platforms like WhatsApp™, (Facebook Inc, Cambridge, MA, USA) by text messages for data collection. Google forms is one of the online data collection tools that is commonly used for surveys [16,17]. If any participant did not install WhatsApp™ on his phone, they were requested to provide an alternative mobile number with WhatsApp™ installed. This was done to enhance the participation rate.

WhatsApp™ is a popular medium for communication and has been used in many studies as an electronic platform for communication [18,19]. Once the survey link was forwarded, the participants were requested to save the sender number first and then to activate the survey link. Prior to inclusion in the survey, the participants were required to offer informed e-consent. A total of three reminders at a gap of one to two days were sent to participants who did respond to

the survey link sent earlier. The study was approved by the Institute Ethics Committee of the institution.

A nominal group technique was used to develop the questionnaire. One researcher developed first draft of the study tool after extensive review of the relevant published papers to ensure all possible ocular symptoms. The questionnaire was revised based on the feedback received from optometrists during the group discussions (in person and online). The questionnaire included demographic information and possible risk factors of mucormycosis. Pre-testing of the questionnaire was done among ten non study persons who had recovered from COVID-19 for standardization purpose. The English language questionnaire was translated into local language Hindi by a translator and back translated into English to ensure the accuracy of the translation.

By clicking on the link, the participants could see the study's aims and objectives and the patient information sheet. The study questionnaire comprised of socio-demographic information of the participants, COVID-19 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) positivity date and presenting symptoms. Pre and post COVID-19 health status was recorded including co-morbidities like diabetes mellitus, hypertension and duration of steroid usage along with awareness about mucormycosis was also recorded.

Study definitions

Post COVID-19 symptoms: Symptom(s) that persisted beyond four weeks from the date of SARS-CoV-2 positive test conducted using either RT-PCR or Cartridge Based Nucleic Acid Amplification Test (CBNAAT). Further, according to timeframe, ocular COVID-19 symptoms were classified as short-term COVID-19 symptoms: symptoms present beyond four weeks after the SARS-CoV-2 positive test and lasting less than or up to twelve weeks; and long-term ocular COVID-19 symptoms: symptoms present beyond twelve weeks after SARS-CoV-2 positive test.

Statistical analysis

Descriptive statistics were performed for the background characteristics of the participants. A multivariate linear regression model was fitted to find the association between mucormycosis knowledge and awareness status with other predictors. Regression models were fitted to investigate the contributory role of the studied variables on mucor-mycosis knowledge and awareness. The p-value < 0.05 was considered statistically significant at 95% confidence interval. Data were analyzed by using statistical software STATA-16. Since it was web-based survey, the CHERRIES checklist guidelines were followed while reporting the data [20].

Results

A total of 242 participants out of 427 completed the study questionnaire, giving a response rate of 56.7%. Approximately 53.7% of participants were male and 46.3% were females (Table 1 and Figure 1).

Most of the participants were working. Among males, the most common occupation was private job (34.6%) and among females the most common occupation was house-wife (65.2%) (Figure 2).

Awareness about mucormycosis was high, especially through social media. A total of 173 (71.2%) of the respondents had heard about black fungus (mucormycosis) (Figure 3).

Around 10.7% were post graduate, 33.5% were graduate, 14.0% were undergraduate and 41.7% were educated up to 10th class or

Table 1: Age and gender distribution of the study participants (N=242).

Age Groups (in years)	Male (%)	Female (%)	Total
0-19	3 (2.3)	5 (4.5)	8 (3.3)
20-29	25 (19.2)	23 (20.5)	48 (19.8)
30-39	20 (15.4)	15 (13.4)	35 (14.5)
40-49	32 (24.6)	23 (20.5)	55 (22.7)
50-59	26 (20.0)	42 (37.5)	68 (28.1)
≥60	24 (18.5)	4 (3.6)	28 (11.6)
Total	130 (53.7)	112 (46.3)	242




Figure 1: Age and gender distribution of study participants (N=242).




Figure 2: Gender and occupation distribution of the study participants (N=242).

below. A statistically significant association was found between being educated, working status and having awareness about mucormycosis (p value < 0.05). Table 2 Presenting symptoms and signs of COVID-19 infection were fever (87.6%), malaise (5.8%), weakness (72.3%), vertigo (5.0%), cough/cold (76.4%), shivering (22.3%), chills (23.1%), loss of taste (61.2 %), rashes (25.6%). Around 5.8% of the patients were asymptomatic and around 84.7% showed multiple signs and symptoms (Figure 4).

Pre-COVID health status showed that 71.9% patients were healthy, 14.0% were unhealthy, and 11.6% were having average health status before COVID-19 infection. However, there was no statistically significant correlation between health status before and after COVID-19 infection (p value 0.962). Table 3 Diabetic mellitus was present in 16.9% of the participants by patient self-report, and 24.7% of the participants reported themselves as hypertensives.

Proportion of Mucormycosis: A total of 46 patients (19.4%) gave history of mucormycosis. Although the diagnosis could not be confirmed from a self-reported questionnaire, the determinants and socio-demographic factors associated with the disease were studied.

Table 2: Socio-demographic parameters of the participants based on awareness about mucormycosis (N=242).

	Heard of mucormycosis (black fungus)			p value
	Yes (%)	No (%)	Total	
Education				0.0007*
10 th Class and below	58 (33.5)	43 (62.3)	101 (41.7)	
Undergraduate	29 (16.8)	5 (7.2)	34 (14.0)	
Graduate	63 (36.4)	18 (26.1)	81 (33.5)	
Post-Graduate	23 (13.3)	3 (4.3)	26 (10.7)	
Gender				0.086
Male	99 (76.2)**	31 (23.8)**	130 (53.7)	
Female	74 (66.1)	38 (33.9)	112 (46.3)	
Age (mean ± SD)	41.87 (±13.62)	44.65 (±12.21)		0.963
Occupation				0.0001*
Working/Studying	97 (56.1)	20 (28.9)	117 (48.3)	
Not Working	76 (43.9)	49 (71.0)	125 (51.7)	
Total	173 (71.2)**	69 (28.8)**	242	

*statistically significant p value **row percentages.

Table 3: Pre-COVID and Post-COVID health status among the study participants.

Health status	Pre-COVID (%)	Post-COVID (%)	(rho ρ)	p value
Unhealthy	34 (14.0)	27 (11.2)	Pearson Correlation Coefficient =0.003	0.962
Average	28 (11.6)	92 (38.0)		
Healthy	174 (71.9)	85 (35.1)		
Very Healthy	6 (2.5)	38 (15.7)		
Total	242	242		




Figure 3: Pie chart showing mode of awareness about mucormycosis among the aware participants (N=242).

A statistically significant association was found between reported history of mucor-mycosis and duration of steroid use (p value=0.003), being educated and aware about the disease (p value=0.000) and older age (p value=0.000) (Table 4).

Discussion

The World Health Organization declared the COVID-19 a pandemic on March 22, 2020, around three months after the first case of the disease was identified [21,22]. Since then, the disease continues to spread in an unprecedented manner across the world causing loss of millions of lives. As of May 24th, 2022, there have been 523 million confirmed cases of COVID-19 and nearly 6.3 million people have lost their lives due to the diseases [1]. In India, around 43 million have been infected with the virus and more than 525 thousand persons have died [1].

While the countries continue to grapple with the rising number of COVID-19 cases, there is growing evidence on lingering COVID-19 symptoms extending up to a few months from the initial diagnosis




Figure 4: Presenting signs and symptoms of COVID-19 infection among study participants (N=242).

Table 4: Association between socio-demographic factors, pre-existing health impairments and steroid therapy with history of mucor-mycosis in the study participants (N=242).

Determinants	History of mucor-mycosis			p value
	Yes (%)	No (%)	Total	
Gender				
Male	22 (47.8)	108 (55.1)	130 (53.7)	0.379
Female	24 (52.2)	88 (44.9)	112 (46.3)	
Age (mean ± SD)	44.59 (±13.19)	35.47 (±13.37)		0.000*
Duration of steroid use (days)	20.96 (± 8.82)	14.51 (± 13.95)		0.003*
Education				
10 th class and below	6 (13.0)	95 (48.5)	101 (41.7)	0.000*
Undergraduate	9 (19.5)	25 (12.8)	34 (14.0)	
Graduate	18 (39.1)	63 (32.1)	81 (33.5)	
Post Graduate	13 (28.3)	13 (6.6)	26 (10.7)	
PreCOVID-19 Health				
Unhealthy	4 (8.7)	30 (15.3)	34 (14.0)	0.018
Average	5 (10.9)	23 (11.7)	28 (11.6)	
Healthy	33 (71.7)	141 (71.9)	174 (71.9)	
Very Healthy	4 (8.7)	2 (1.0)	6 (2.5)	
H/o Diabetes Mellitus				
Yes	5 (10.9)	36 (18.4)	41 (16.9)	0.227
No	41 (89.1)	160 (81.6)	201 (83.1)	
H/o Hypertension				
Yes	10 (21.7)	50 (25.5)	60 (24.8)	0.610
No	36 (78.3)	146 (74.5)	182 (75.2)	
Total	46 (19.0)	196 (80.9)	242	

*Statistically significant p value.

among the survivors. Mucor-mycosis had been recognized as a post COVID-19 disease in many studies. The number of cases identified during the pandemic is much higher than those reported in the literature in different settings in the pre-pandemic era [23]. Non-ocular manifestations of mucor-mycosis, like renal mucor-mycosis was reported by many authors, even before the pandemic [24]. After the onset of the pandemic, mucor-mycosis of the paranasal sinuses with intra-orbital extension was reported by many studies [25-27].

Uncontrolled diabetes and history of steroid use during coronavirus treatment have been recognized as risk factors for mucor-mycosis by previous studies [25,28,29] and the current study found a significant association with the duration of steroid use.

The current online study had a response rate of 56.8% and participation rates range from 50-80% in online surveys around the globe. The pandemic presented unique opportunities to conduct online studies around the globe. The study found that knowledge and awareness about mucor-mycosis is good in post COVID-19 recovered patients in Indian population. Alongside, numerous predictors like education, age, duration of steroid treatment for COVID-19 were found significantly associated with mucormycosis.

The older age groups were found to be less knowledgeable about mucormycosis compared to the younger age group, although the difference was not statistically significant. This study found that mucormycosis knowledge and awareness was less in female than male, and working people have more knowledge and awareness than non-working people. A previous study had revealed that the males had more knowledge about COVID-19 than their females counterparts in Bangladesh [30]. The same study also demonstrated Knowledge was significantly correlated with age (p<0.005), an education level (p<0.001), attitude (p<0.001), and urban location (p<0.001) [30].

A significant relationship was found between the history of mucormycosis and pre COVID-19 health.

Two previous studies among thirty-one and fifteen patients of mucor-mycosis reported a mean age of 56.3 years and median of 52 years (range 14-71) respectively, which is higher than the mean age of 44.6 years reported in the current study [28,31]. A younger age profile can be explained by the fact that non-probability sampling and online data collection led to selection of a greater number of younger participants.

Older age was associated with mucor-mycosis in the current study, in conformity with previous studies [29].

The strength of the current study is that awareness and history of mucormycosis was assessed in individuals hospitalized as well as not admitted to hospital giving a better representation of the population. The limitations of the study are that sample size is small and it is not representative of the general population, since only purposive and conveniently sampled individuals were covered and data was collected using either smartphones or WhatsApp™. Those not having access to smartphones could not be included in the study. The reverse causality between predictors and mucormycosis could not be established, as the study was not longitudinal.

A larger study with more sample size, especially community-based studies will give a more representative picture of the mucormycosis problem among post COVID-19 recovered patients. Fungal infection and mucormycosis are not new phenomena but the emergence of mucormycosis associated with COVID-19 is a big concern. This study documented that there was good knowledge and awareness about mucormycosis in post COVID-19 recovered patients. The knowledge and awareness about mucormycosis varies with age, gender, socio-economic status, literacy and occupation. Efforts to increase awareness about black fungus (mucormycosis) should be directed towards females, older age groups and persons not employed or out of the active workforce. The duration of steroid therapy should be closely monitored and all precautions for the prevention of mucormycosis should be taken in hospitalized patients.

With millions of individuals recovering, the consequence of COVID-19 is likely to become an additional burden on the health care delivery system. Understanding mucor-mycosis and its associated

risk factors is crucial to reorient the eye infrastructure to make it more responsive to the growing needs for this disease. Hence, the current study can be used to guide the development of appropriate infrastructure and manpower thereby designing management strategies and patients care plan in hospital and rehabilitation facilities.

A major recommendation from the study is an integrated care model involving all relevant healthcare disciplines while managing mucor-mycosis in the outpatient setting at every healthcare facility, rather than organ-specific approaches. Continuous follow-up will be important to assess the further prolonged mucormycosis related health problems. A community-based rehabilitation program, including psychological support should be a part of post COVID-19 care.

Another important recommendation from the study will be to make policies and planning of developing awareness in the general public about this dreadful blinding orbital disease.

References

1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data.
2. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). In *Treasure Island (FL)*; 2022.
3. Aranjani JM, Manuel A, Abdul Razack HI, Mathew ST. COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India. *PLoS Negl Trop Dis*. 2021 Nov 18; 15(11): e0009921.
4. Bhatt K, Agolli A, Patel MH, Garimella R, Devi M, Garcia E, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. *Discov (Craiova, Rom)*. 2021 Mar 31; 9(1): e126–e126.
5. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. *Clin Microbiol Rev*. 2005 Jul; 18(3): 556–69.
6. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. *Mycopathologia*. 2021/02/05. 2021 May; 186(2): 289–98.
7. WHO/Europe | Coronavirus disease (COVID-19) outbreak - About the virus [Internet]. [cited 2022 May 31]. Available from: <https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov>
8. Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. *Microorganisms*. 2021 Mar 4; 9(3): 523.
9. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2005 Sep; 41(5): 634–53.
10. Sen M, Honavar SG, Sharma N, Sachdev MS. COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19. *Indian J Ophthalmol*. 2021; 69(3).
11. Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol*. 2021 Jul; 69(7): 1670–92.
12. Ramaswami A, Sahu AK, Kumar A, Suresh S, Nair A, Gupta D, et al. COVID-19-associated mucormycosis presenting to the Emergency Department-an observational study of 70 patients. *QJM*. 2021 Nov; 114(7): 464–70.
13. Satish D, Joy D, Ross A, . B. Mucormycosis coinfection associated with global COVID-19: a case series from India. *Int J Otorhinolaryngol Head Neck Surg*. 2021; 7(5): 815.
14. Mishra N, Mutya VSS, Thomas A, Rai G, Reddy B, M. AA, et al. A case series of invasive mucormycosis in patients with COVID-19 infection. *Int J Otorhinolaryngol Head Neck Surg*. 2021; 7(5): 867.
15. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. *Indian J Ophthalmol*. 2021 Feb; 69(2): 244–52.
16. Karagöz MA, Gül A, Borg C, Erihan İB, Uslu M, Ezer M, et al. Influence of COVID-19 pandemic on sexuality: a cross-sectional study among couples in Turkey. *Int J Impot Res*. 2020 Dec; 1–9.
17. Gondwal R, Pal A, Paul S, Bohra R, Pal A, Aulakh S, et al. Sexual Behavior During the Times of COVID-19-Related Lockdown in India: Results From an Online Survey. *J Psychosexual Heal*. 2020; 2(4): 242–6.
18. Singer B, Walsh CM, Gondwe L, Reynolds K, Lawrence E, Kasiya A. WhatsApp as a medium to collect qualitative data among adolescents: lessons learned and considerations for future use. *Gates Open Res* 2020 4130. 2020 Sep; 4:130.
19. Arroz JAH, Candrinho BN, Mussambala F, Chande M, Mendis C, Dias S, et al. WhatsApp: A supplementary tool for improving bed nets universal coverage campaign in Mozambique. *BMC Health Serv Res*. 2019 Feb; 19(1).
20. Eysenbach G. Improving the quality of web surveys: The Checklist for Reporting Results of Internet E-Surveys (CHERRIES). *J Med Internet Res*. 2004; 6(3).
21. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2021 Nov 3].
22. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med*. 2020 Feb; 382(8): 727–33.
23. Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, et al. Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic. *Front Med*. 2021; 8.
24. Devana SK, Gupta VG, Mavuduru RS, Bora GS, Sharma AP, Parmar KM, et al. Isolated Renal Mucormycosis in Immunocompetent Hosts: Clinical Spectrum and Management Approach. *Am J Trop Med Hyg [Internet]*. 2019 Apr; 100(4): 791–7.
25. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol*. 2021 May; 135(5): 442–7.
26. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Vol. 39, *Indian journal of medical microbiology*. 2021. p. 380–3.
27. Arjun R, Felix V, Niyas VKM, Kumar MAS, Krishnan RB, Mohan V, et al. COVID-19-associated rhino-orbital mucormycosis: a single-centre experience of 10 cases. *QJM*. 2022 Jan; 114(11): 831–4.
28. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. *Indian J Ophthalmol*. 2021 Jun; 69(6): 1563–8.
29. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. *Emerg Infect Dis*. 2021 Sep; 27(9): 2349–59.

30. Hossain MA, Jahid MIK, Hossain KMA, Walton LM, Uddin Z, Haque MO, et al. Knowledge, attitudes, and fear of COVID-19 during the Rapid Rise Period in Bangladesh. *PLoS One*. 2020 Sep 24; 15(9): e0239646–e0239646.
31. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. *Mycoses*. 2021 Oct; 64(10): 1238–52.